Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

(2012) Jolieke G van Oosterwijk et al.   BMC CANCER

Global tumor protein p53/p63 interactome

(2012) Yiping Huang et al.   CELL CYCLE

PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics

(2012) Kiran Mahajan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance

(2011) J. G. van Oosterwijk et al.   ANNALS OF ONCOLOGY

The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro

(2011) Philipp Lechler et al.   BMC CANCER

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Curcumin Modulates MicroRNA-203-Mediated Regulation of the Src-Akt Axis in Bladder Cancer

(2011) S. Saini et al.   Cancer Prevention Research

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function

(2011) S Donzelli et al.   CELL DEATH AND DIFFERENTIATION

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

Small-molecule inhibitors of the PI3K signaling network

(2011) Colleen R McNamara et al.   Future Medicinal Chemistry

IGF-I enhances α5β1 integrin expression and cell motility in human chondrosarcoma cells

(2011) Chi-Ming Wu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

(2011) M Fernanda Amary et al.   JOURNAL OF PATHOLOGY

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome

(2011) Twinkal C Pansuriya et al.   NATURE GENETICS

Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas

(2010) MIRVA SÖDERSTRÖM et al.   APMIS

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

(2010) F. Ravandi et al.   BLOOD

Fyn

(2010) Yoshihito D. Saito et al.   CANCER

Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

(2010) G. Zauli et al.   CLINICAL CANCER RESEARCH

Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells

(2010) Raffaella Bosco et al.   INVESTIGATIONAL NEW DRUGS

Prolactin Enhances Insulin-like Growth Factor I Receptor Phosphorylation by Decreasing Its Association with the Tyrosine Phosphatase SHP-2 in MCF-7 Breast Cancer Cells

(2010) Kristopher C. Carver et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

GSK-3β promotes cell survival by modulating Bif-1-dependent autophagy and cell death

(2010) Jun Yang et al.   JOURNAL OF CELL SCIENCE

Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment

(2009) Y. M. Schrage et al.   CANCER RESEARCH

Roles of Fyn in pancreatic cancer metastasis

(2009) Zhi-Yu Chen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The Role of Src in Solid Tumors

(2009) D. L. Wheeler et al.   ONCOLOGIST

FYNis overexpressed in human prostate cancer

(2008) Edwin M. Posadas et al.   BJU INTERNATIONAL

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

(2008) Lilian Amrein et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Clinical Approach Towards Chondrosarcoma

(2008) H. Gelderblom et al.   ONCOLOGIST